Summary
Check out our latest interview with SOPHiA GENETICS, a company revolutionizing healthcare by leveraging data-driven technology to improve the diagnosis and treatment of cancer and rare diseases. In this conversation with Paul Chilo, Director of Governance, Risk & Compliance, we explore UNITY, a global oncology platform, and discuss the compliance strategy behind this international initiative, as well as our collaboration in making it a reality.
Here is the latest interview with one of our clients - SOPHiA GENETICS,. SOPHiA GENETICS was founded in 2011 by biologists who saw an opportunity to address the growing need for answers to diseases of the DNA.
They believed technology could make a positive and lasting impact on the world, using data for good.Their vision was to build a future in which each patient has equal access to world-class care, and today, they are well underway to realizing that impact. SOPHia has built a technology platform that distills complex data into actionable insights to reshape the way that cancer and rare inherited disorders are diagnosed and treated.
In this interview with Paul Chilo, Director of Governance, Risk & Compliance at SOPHiA GENETICS, we explore the latest initiative, UNITY, a global oncology platform. We discuss SOPHiA GENETICS’ compliance strategy for this international project, as well as our collaboration and partnership in bringing it to life.
Sign up for our newsletter
We like to keep our readers up to date on complex regulatory issues, the latest industry trends and updated guidelines to help you to solve a problem or make an informed decision.
Sign up for our newsletter
We like to keep our readers up to date on complex regulatory issues, the latest industry trends and updated guidelines to help you to solve a problem or make an informed decision.
Vendor GDPR in Clinical Trials: What the IQVIA CNIL Ruling Changes for Sponsors and Healthtech Companies
On 26 May 2026 the CNIL fined IQVIA Operations France EUR 5 million for failures in its two authorised health data warehouses, LRX and EMR. The decision exposes weaknesses in CRO data protection practice that have direct consequences for every pharmaceutical sponsor relying on a CRO to process patient, prescription or trial data. This article unpacks the four areas of failure, explains why pseudonymisation no longer offers the cover many sponsors assume, and sets out a practical oversight checklist for sponsor data controllers.
EU AI Act for Healthcare: What Life Sciences Companies Need to Know before August 2026
EU AI Act 2026 healthcare enforcement requires immediate compliance to avoid penalties.
Navigating US Regulatory Requirements for AI-Powered Medical Devices: A Comprehensive Guide to FDA, HIPAA, and IRB Compliance
US AI medical device compliance requires navigating FDA, HIPAA, IRBs, and consent waivers strategically.
FAQs
Our frequently questions